Eintrag weiter verarbeiten
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Gespeichert in:
| Zeitschriftentitel: | Breast Care |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| In: | Breast Care, 11, 2016, 5, S. 315-322 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
S. Karger AG
|
| Schlagwörter: |
| author_facet |
Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. |
|---|---|
| author |
Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. |
| spellingShingle |
Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. Breast Care Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study Oncology Surgery |
| author_sort |
gaß, paul |
| spelling |
Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. 1661-3791 1661-3805 S. Karger AG Oncology Surgery http://dx.doi.org/10.1159/000452468 <jats:p><b><i>Background:</i></b> Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. <b><i>Methods:</i></b> Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. <b><i>Results:</i></b> In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. <b><i>Conclusion:</i></b> There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.</jats:p> Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study Breast Care |
| doi_str_mv |
10.1159/000452468 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0NTI0Njg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0NTI0Njg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
S. Karger AG, 2016 |
| imprint_str_mv |
S. Karger AG, 2016 |
| issn |
1661-3791 1661-3805 |
| issn_str_mv |
1661-3791 1661-3805 |
| language |
English |
| mega_collection |
S. Karger AG (CrossRef) |
| match_str |
gass2016factorsinfluencingdecisionmakingfororagainstadjuvantandneoadjuvantchemotherapyinpostmenopausalhormonereceptorpositivebreastcancerpatientsintheevaluatetmstudy |
| publishDateSort |
2016 |
| publisher |
S. Karger AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Breast Care |
| source_id |
49 |
| title |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_unstemmed |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_full |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_fullStr |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_full_unstemmed |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_short |
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_sort |
factors influencing decision-making for or against adjuvant and neoadjuvant chemotherapy in postmenopausal hormone receptor-positive breast cancer patients in the evaluate-tm study |
| topic |
Oncology Surgery |
| url |
http://dx.doi.org/10.1159/000452468 |
| publishDate |
2016 |
| physical |
315-322 |
| description |
<jats:p><b><i>Background:</i></b> Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. <b><i>Methods:</i></b> Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. <b><i>Results:</i></b> In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. <b><i>Conclusion:</i></b> There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.</jats:p> |
| container_issue |
5 |
| container_start_page |
315 |
| container_title |
Breast Care |
| container_volume |
11 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347571740475397 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:54:59.069Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Factors+Influencing+Decision-Making+for+or+against+Adjuvant+and+Neoadjuvant+Chemotherapy+in+Postmenopausal+Hormone+Receptor-Positive+Breast+Cancer+Patients+in+the+EvAluate-TM+Study&rft.date=2016-01-01&genre=article&issn=1661-3805&volume=11&issue=5&spage=315&epage=322&pages=315-322&jtitle=Breast+Care&atitle=Factors+Influencing+Decision-Making+for+or+against+Adjuvant+and+Neoadjuvant+Chemotherapy+in+Postmenopausal+Hormone+Receptor-Positive+Breast+Cancer+Patients+in+the+EvAluate-TM+Study&aulast=L%C3%B6hberg&aufirst=Christian+R.&rft_id=info%3Adoi%2F10.1159%2F000452468&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347571740475397 |
| author | Gaß, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peyman, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Löhberg, Christian R. |
| author_facet | Gaß, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peyman, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Löhberg, Christian R., Gaß, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peyman, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Löhberg, Christian R. |
| author_sort | gaß, paul |
| container_issue | 5 |
| container_start_page | 315 |
| container_title | Breast Care |
| container_volume | 11 |
| description | <jats:p><b><i>Background:</i></b> Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. <b><i>Methods:</i></b> Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. <b><i>Results:</i></b> In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. <b><i>Conclusion:</i></b> There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.</jats:p> |
| doi_str_mv | 10.1159/000452468 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDA0NTI0Njg |
| imprint | S. Karger AG, 2016 |
| imprint_str_mv | S. Karger AG, 2016 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1661-3791, 1661-3805 |
| issn_str_mv | 1661-3791, 1661-3805 |
| language | English |
| last_indexed | 2024-03-01T17:54:59.069Z |
| match_str | gass2016factorsinfluencingdecisionmakingfororagainstadjuvantandneoadjuvantchemotherapyinpostmenopausalhormonereceptorpositivebreastcancerpatientsintheevaluatetmstudy |
| mega_collection | S. Karger AG (CrossRef) |
| physical | 315-322 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | S. Karger AG |
| record_format | ai |
| recordtype | ai |
| series | Breast Care |
| source_id | 49 |
| spelling | Gaß, Paul Fasching, Peter A. Fehm, Tanja de Waal, Johann Rezai, Mahdi Baier, Bernd Baake, Gerold Kolberg, Hans-Christian Guggenberger, Martin Warm, Mathias Harbeck, Nadia Wuerstlein, Rachel Deuker, Jörg-Uwe Dall, Peter Richter, Barbara Wachsmann, Grischa Brucker, Cosima Siebers, Jan W. Fersis, Nikos Kuhn, Thomas Wolf, Christopher Vollert, Hans-Walter Breitbach, Georg-Peter Janni, Wolfgang Landthaler, Robert Kohls, Andreas Rezek, Daniela Noesselt, Thomas Fischer, Gunnar Henschen, Stephan Praetz, Thomas Heyl, Volker Kühn, Thorsten Krauss, Thomas Thomssen, Christoph Hohn, Andre Tesch, Hans Mundhenke, Christoph Hein, Alexander Rauh, Claudia Bayer, Christian M. Jacob, Adib Schmidt, Katja Belleville, Erik Hadji, Peyman Brucker, Sara Y. Beckmann, Matthias W. Wallwiener, Diethelm Kümmel, Sherko Löhberg, Christian R. 1661-3791 1661-3805 S. Karger AG Oncology Surgery http://dx.doi.org/10.1159/000452468 <jats:p><b><i>Background:</i></b> Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. <b><i>Methods:</i></b> Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. <b><i>Results:</i></b> In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. <b><i>Conclusion:</i></b> There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues.</jats:p> Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study Breast Care |
| spellingShingle | Gaß, Paul, Fasching, Peter A., Fehm, Tanja, de Waal, Johann, Rezai, Mahdi, Baier, Bernd, Baake, Gerold, Kolberg, Hans-Christian, Guggenberger, Martin, Warm, Mathias, Harbeck, Nadia, Wuerstlein, Rachel, Deuker, Jörg-Uwe, Dall, Peter, Richter, Barbara, Wachsmann, Grischa, Brucker, Cosima, Siebers, Jan W., Fersis, Nikos, Kuhn, Thomas, Wolf, Christopher, Vollert, Hans-Walter, Breitbach, Georg-Peter, Janni, Wolfgang, Landthaler, Robert, Kohls, Andreas, Rezek, Daniela, Noesselt, Thomas, Fischer, Gunnar, Henschen, Stephan, Praetz, Thomas, Heyl, Volker, Kühn, Thorsten, Krauss, Thomas, Thomssen, Christoph, Hohn, Andre, Tesch, Hans, Mundhenke, Christoph, Hein, Alexander, Rauh, Claudia, Bayer, Christian M., Jacob, Adib, Schmidt, Katja, Belleville, Erik, Hadji, Peyman, Brucker, Sara Y., Beckmann, Matthias W., Wallwiener, Diethelm, Kümmel, Sherko, Löhberg, Christian R., Breast Care, Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study, Oncology, Surgery |
| title | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_full | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_fullStr | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_full_unstemmed | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_short | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| title_sort | factors influencing decision-making for or against adjuvant and neoadjuvant chemotherapy in postmenopausal hormone receptor-positive breast cancer patients in the evaluate-tm study |
| title_unstemmed | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
| topic | Oncology, Surgery |
| url | http://dx.doi.org/10.1159/000452468 |